Attraverso questo bando la fondazione accoglie proposte da parte di tutte le scienze naturali e sociali e le scienze umane che promettono di aumentare la comprensione delle cause, delle manifestazioni e del controllo della violenza e dell’aggressione. La massima priorità è data alla ricerca che può aumentare la comprensione e il miglioramento dei problemi urgenti […]
The Harry Frank Guggenheim Foundation – Research Grants Leggi tutto »
NIHR – National Institute for Health Research e UKRI – UK Research and Innovation hanno lanciato un bando per progetti di ricerca su temi di alta priorità legati al Covid-19 a rapida implementazione, ovvero che producano effetti sulla salute pubblica nell’arco di al massimo 12 mesi. Le proposte riguardano l’identificazione e la mitigazione degli effetti
AIM supports innovative, high-impact research that will foster new directions, bring new perspectives to the field, and address neglected issues in FA research. This RFP promotes the initial exploration of high-risk, high-gain, and potentially groundbreaking concepts in FA research. The proposed research project should be innovative and include a well-formulated, testable hypothesis. The presentation of
Friedreich’s Ataxia Research Alliance – Award for Innovative Mindset (AIM) Leggi tutto »
L’obiettivo del bando è l’aumento del numero di trattamenti nuovi per la malattia di Alzheimer, le demenze correlate e l’invecchiamento cognitivo (studi clinici pilota basati su biomarker per i test di sicurezza di Alzheimer, così come i test di sicurezza di fase 1) Le proposte progettuali possono avere una durata variabile e il finanziamento massimo è
Alzheimer’s Drug Discovery Foundation – Program to Accelerate Clinical Trials (PACT) Leggi tutto »
Through its Prevention beyond the pipeline Program, the ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Duration: One year for epidemiological analyses Varies (multi-year) for clinical trials Average award: $50,000-$100,000 for epidemiological analyses
Alzheimer’s Drug Discovery Foundation – Prevention beyond the pipeline Leggi tutto »
Given the pathological heterogeneity of Alzheimer’s disease and related dementias, new biomarkers are needed to more accurately characterize specific underlying pathophysiology. This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use (see below) that include but are not limited to: Clearly demonstrate target engagement for novel therapeutics The
Purpose: To support innovative research that will advance the existing knowledge base in the areas of health care financing, delivery, management and/or policy. Studies must have strong potential to yield insights that can be used to have a positive impact on the U.S. health care system by reducing spending, improving quality of care, and/or expanding
The National Institute for Health Care Management (NIHCM) Research Grants 2020 Leggi tutto »
The Therapeutic Pipeline Program is open to industry and academic investigators proposing novel approaches or repositioning approved or clinically safe therapies from other disease indications. Part of our Edmond J. Safra Core Programs for PD Research, the Therapeutic Pipeline Program advances Parkinson’s disease therapeutic and intervention development along the pre-clinical and clinical path. Applications should focus on studies
The Michael J.Fox Foundation for Parkinson’s Research – Therapeutic Pipeline Program Leggi tutto »
The Target Advancement Program is open to industry and academic investigators proposing to build conclusive evidence to rationalize biological targets and pathways for Parkinson’s disease (PD) therapeutic development. Part of our Edmond J. Safra Core Programs for PD Research, this program will support projects focused on validating targets and defining pathways implicated in PD pathological processes
Currently, many efforts are focusing on understanding the role of various cellular processes/pathways in PD and uncovering novel targets within these pathways for therapeutic development. As such, sensitive biomarker readouts for these pathways will be critical for bridging the gap from basic to translational research and clinical trials. The Parkinson’s Pathway Biomarkers program is open
